84691-16-7

Basic information

• Product Name: 3-Isoxazolecarboxylicacid,4-hydroxy-,ethylester(9CI)
• Synonyms: 3-Isoxazolecarboxylicacid,4-hydroxy-,ethylester(9CI);ethyl 4-hydroxyisoxazole-3-carboxylate
• CAS NO: 84691-16-7
• Molecular Formula: C₆H₇NO₄
• Molecular Weight: 157.12
• Product Categories: OXAZOLE
• Mol File: 84691-16-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 252.1±20.0 °C(Predicted)
• Appearance: /
• Density: 1.328±0.06 g/cm3(Predicted)
• PKA: 7.66±0.15(Predicted)
• CAS DataBase Reference: 3-Isoxazolecarboxylicacid,4-hydroxy-,ethylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Isoxazolecarboxylicacid,4-hydroxy-,ethylester(9CI)(84691-16-7)
• EPA Substance Registry System: 3-Isoxazolecarboxylicacid,4-hydroxy-,ethylester(9CI)(84691-16-7)

Safety Data

• Hazardous Substances Data: 84691-16-7(Hazardous Substances Data)

Usage

Properties

1. Chemical compound: 3-Isoxazolecarboxylic acid, 4-hydroxy-, ethyl ester (9CI)
2. Classification: Isoxazolecarboxylic acid derivative
3. Structure: Ethyl ester of 4-hydroxy-3-isoxazolecarboxylic acid

Specific content

1. Potential intermediate: It is a potential intermediate in the synthesis of various pharmaceutical compounds.
2. Medicinal chemistry: It may have potential applications in the field of medicinal chemistry.
3. Drug development: It may have potential uses in drug development.
4. Structural properties: Its structure provides unique properties and functional groups.
5. Further research: More research is required to fully understand its chemical and biological properties.
6. Pharmaceutical industry: It may have potential uses in the pharmaceutical industry.

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 110-46-3 isopentyl nitrite 
• 66340-85-0 ethyl 4-bromo-2-hydroxyimino-3-oxobutyrate 
• 50382-11-1 ethyl γ-chloro-α-oximinoacetoacetate 
• 75689-07-5 ethyl 4-bromo-2-(hydroxyimino)-3-oxobutanoate 
• 13176-46-0 4-bromoethyl acetoacetate 
• 141-97-9 ethyl acetoacetate 

Relevant articles and documents

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula II.

GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III); wherein R1c, R2C, R4C, Wc, Yc, Zc and Gc, are defined herein.

HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE

The present application relates to novel heterocyclically substituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.